Six states with laws enabling the importation of prescription drugs from Canada – Vermont, Florida, Maine, Colorado, New Mexico, and New Hampshire – are awaiting publication of federal rules currently under review by the Office of Management and Budget. They are eager to see if the final rules address key concerns submitted by the National […]
Author Archive for: trish-riley
About Trish Riley
Trish Riley is executive director of the National Academy for State Health Policy (NASHP) and president of its corporate board. She helped build NASHP as CEO from 1988 to 2003.
Previously, she was a senior fellow in State Health Policy at George Washington University and at the Muskie School of Public Service, University of Southern Maine. From 2003 to 2011, she served as director of the Maine Governor’s Office of Health Policy and Finance, leading Maine’s effort to develop a comprehensive, coordinated state health system that included increasing access to affordable health insurance. She was the principal architect of Dirigo Health Reform and served as Maine’s liaison to the federal government and Congress, particularly during deliberations around national health reform. She chaired the Governor’s Steering Committee to develop a plan to implement the Affordable Care Act in Maine.
Riley has also held appointed positions under five Maine governors, directing the Office on Aging, Medicaid and state health agencies, and health planning and licensing programs.
Riley has published and presented widely about state health reform. She served as a member of the Kaiser Commission on Medicaid and the Uninsured, the Medicaid and CHIP Payment and Access Commission (MACPAC), the Health Services Committee of the Institute of Medicine, the National Academy for Social Insurance, and the board of directors of Maine’s co-op insurance plan. She was a member of the Institute of Medicine’s Subcommittee on Creating an External Environment for Quality. She also previously served as a member of the board of directors of the National Committee on Quality Assurance. Riley holds a BS and MS from the University of Maine.
Entries by Trish Riley
Results from a new RAND Corporation study – Nationwide Evaluation of Health Care Prices Paid By Private Health Plans – show commercial payers reimburse hospitals about 2.5-times more than does Medicare. As expected, hospital officials responded, claiming that public payers underpay for medical services and that it is inappropriate to challenge hospitals now as they battle […]
Last week, Pennsylvania State Sen. Senator Thomas Killion submitted a first-in-the-nation proposal to reduce drug costs in his state using a new international drug pricing model law developed by the National Academy for State Health Policy (NASHP). The International Reference Rates model law “imports” Canadian prices, which can cost 80 percent less than in the […]
Last week, over 1,000 state health policy leaders and others from every state joined the National Academy for State Health Policy’s (NASHP) first-ever virtual state health policy conference to discuss a path forward during an unrelenting pandemic and profound budget challenges. As one state official noted, “This was a chance to lift my eyes from […]
Frustrated that their constituents pay far more for prescription drugs than residents of other nations, many state policymakers have embraced Canadian drug importation. Six groundbreaking states, led by Vermont, have enacted laws to enable importation but still need federal approval to begin. Proposed rules, which President Trump recently touted in an Executive Order, still need […]
Unpredictable and unrelenting drug price increases drive up health insurance premiums and challenge states’ public purchasers as they weigh escalating costs against balanced budget requirements. The National Academy for State Health Policy’s (NASHP) newest model law, an Act to Protect Consumers from Unsupported Price Increases on Prescription Drugs, levies hefty fines on manufacturers that impose […]
The recent decision to shift daily data reported by hospital administrators about their capacity and hospital beds occupied by COVID-19 patients from the Centers for Disease Control and Prevention (CDC) to the Department of Health and Human Services’ (HHS) TeleTracking system has sparked concerns among state officials who are on the pandemic’s frontline, and infectious […]
Getting a grip on pharmaceutical manufacturers’ pricing strategies is a 2020 priority for the National Academy for State Health Policy (NASHP), but how drugs are marketed also significantly impacts spending on drugs. In 2016, pharmaceutical companies spent $6 billion on direct-to-consumer advertising, but a whopping $20.3 billion to market their brand name drugs to health […]
As the nation grapples with the pandemic, new research has identified dexamethasone, a low-cost generic drug, as a promising treatment for certain COVID-19 patients. But consumers worry – will its cost remain low? Will new treatments be affordable?
COVID-19 has profoundly affected the health care landscape, raising anew concerns about the high cost of hospitalizations while simultaneously placing new burdens on those facilities and curtailing non-emergency services. Providers, unable to see patients for routine care, lost revenue and many free-standing physician practices are now at risk, and now face increasing pressure to merge […]